Design, synthesis and biological evaluation of tasiamide analogues as tumor inhibitors.

Abstract

Eighteen analogues of the marine cytotoxic linear peptide tasiamide were designed, synthesized and screened for their inhibitory activities against the growth of human nasopharyngeal carcinoma (KB) and human non-small cell lung tumor (A549) cell lines. The results indicated that minor modifications of the C-terminus with aromatic groups were tolerated, with the IC₅₀ values between 1.29 and 12.88 μM against these two cancer cell lines. Truncation, minor modifications at the N-terminus or elimination of the N-methyl groups in N-Me-D-Gln and/or N-Me-D-Phe residues resulted in inactive analogues.

• Authors: Wei Zhang, Tiantian Sun, Zhenhua Ma, Yingxia Li
• Journal: Marine drugs (Mar Drugs) Vol. 12 Issue 4 Pg. 2308-25 (Apr 22 2014) ISSN: 1660-3397 [Electronic] Switzerland
• PMID: 24759000 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Oligopeptides
• tasiamide

Topics

• Antineoplastic Agents (chemical synthesis, chemistry, pharmacology)
• Carcinoma
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Cell Line, Tumor
• Humans
• Inhibitory Concentration 50
• Lung Neoplasms (drug therapy, pathology)
• Nasopharyngeal Carcinoma
• Nasopharyngeal Neoplasms (drug therapy, pathology)
• Oligopeptides (chemical synthesis, chemistry, pharmacology)
• Structure-Activity Relationship